Examining Changes in Nasal IL-1 During Acute Asthma Exacerbation in Adolescents

N/A Completed NCT04748055

Summary

To study the change from baseline in IL-1β (interleukin 1 beta) concentrations in the nasal airway during acute asthma exacerbation, specifically to measure the degree of change and identify the timing of peak IL-1β concentration. This information will allow the investigators to estimate effect size and guide decisions about the optimal timing of anakinra administration for the future study.

Percentage Change From Baseline in Nasal IL-1β (pg/mL) Concentrations During Asthma Exacerbation

Baseline and up to 5 days from the time asthma exacerbation is diagnosed (Months 1-12) · percentage change from baseline

Open in BENITIONS View on ClinicalTrials.gov

Other trials for this condition

• A Study of Remote Asthma Management Using an Integrated Artificial Intelligence-assisted E — Mayo Clinic
• Developing a Childhood Asthma Risk Passive Digital Marker — Indiana University
• A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared With C — Chiesi Farmaceutici S.p.A.
• A Study Evaluating the Efficacy and Safety of Lebrikizumab in Adult Patients With Mild to — Hoffmann-La Roche
• A Study of Lebrikizumab in Participants With Uncontrolled Asthma Who Are on Inhaled Cortic — Hoffmann-La Roche
• Effectiveness and Safety Study of Tezepelumab in Adults & Adolescent Participants With Sev — AstraZeneca

All trials